Immunovant (IMVT) said Monday it appointed director Eric Venker as chief executive, succeeding Pete Salzmann, who has retired.
The company also named Tiago Girao as chief financial officer, succeeding Renee Barnett, who has stepped down from the role. Girao previously served as CFO of Telavant.
Immunovant said the changes are part of a "strategic realignment" under which Roivant Sciences (ROIV) will lead all investor relations activity of the company.
The company said it is expanding the development of IMVT-1402 into two new indications, namely Sjogren's Disease and Cutaneous Lupus Erythematosus.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.